| Bioactivity | Navicixizumab (OMP-305B83) is a bispecific anti-VEGF and anti-DLL4 inhibitory antibody. Navicixizumab can combine with Paclitaxel (HY-B0015) for cancer research. Navicixizumab can be used in the research of ovarian, primary peritoneal, or fallopian tube cancer[1][2][3]. |
| Target | IC50: hVEGF (0.36 nM), mVEGF (25.5 nM), hDLL4 (1.3 nM) |
| Invitro | Navicixizumab (0-100 μM) 在 hVEGF 存在的情况下减少人内皮细胞的增殖[3]. |
| In Vivo | Navicixizumab (15 mg/kg，每周一次，持续 4 周) 抑制结肠异种移植肿瘤的生长[3]。 |
| Name | Navicixizumab |
| CAS | 1638338-43-8 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Fu S, et al. Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. J Clin Oncol. 2022 Aug 10;40(23):2568-2577. [2]. Perez-Fidalgo JA, et al. NOTCH signalling in ovarian cancer angiogenesis. Ann Transl Med. 2020 Dec;8(24):1705. [3]. Wan-Ching Yen, et al. Abstract C164: Dual targeting of the DLL4 and VEGF pathways with a bispecific monoclonal antibody inhibits tumor growth and reduces cancer stem cell frequency. Mol Cancer Ther (2015) 14 (12_Supplement_2): C164. |